Buhtoiarova Tatiana N, Brenner Carol A, Singh Meenakshi
From the Department of Pathology.
Office of the Vice Dean for Faculty Affairs and Faculty Development, Stony Brook University School of Medicine, State University of New York at Stony Brook, Stony Brook.
Am J Clin Pathol. 2016 Jan;145(1):8-21. doi: 10.1093/ajcp/aqv014.
Type II and other high-grade endometrial carcinomas may challenge conventional treatment due to recurrence and metastatic spread and therefore are a persistent clinical dilemma. Effective targeted therapy for these is a goal for clinicians and researchers alike.
An extensive review of the literature has been performed for obtaining an in-depth understanding of the clinicopathological characteristics, etiologic factors, and molecular profile of these subsets of endometrial carcinoma. Progress made with current and emerging biomarkers for prognosis assessment and therapeutic targeting has been summarized.
There has been a significant increase in research on potential biomarkers of endometrial cancer, and beneficial targeted therapies have been identified.
Clinical trials are leading the charge for substantial gains toward personalized treatment of aggressive endometrial carcinoma subtypes.
II型及其他高级别子宫内膜癌可能因复发和转移扩散而对传统治疗构成挑战，因此是一个持续存在的临床难题。针对这些癌症的有效靶向治疗是临床医生和研究人员共同的目标。
对文献进行了广泛综述，以深入了解这些子宫内膜癌亚型的临床病理特征、病因因素和分子特征。总结了目前和新兴的用于预后评估和治疗靶向的生物标志物所取得的进展。
子宫内膜癌潜在生物标志物的研究有了显著增加，并且已经确定了有益的靶向治疗方法。
临床试验正在引领积极推进对侵袭性子宫内膜癌亚型进行个性化治疗的进程。
